Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

• Market Cap: HK$832.42M
• Dividend Yield: N/A
• Average Volume (3M): 686.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: -4.88%
• EPS Growth: -34.75%
• Country: HK
• Employees: 260
• Sector: Basic Materials
• Sector Strength: 68
• Industry: Agricultural Inputs
• EPS (TTM): -0.01
• Shares Outstanding: 1,436,400,000
• 10 Day Avg. Volume: 422,000
• 30 Day Avg. Volume: 686,666
• PEG Ratio: 0.31
• Price to Book (P/B): 4.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

The overall score of 39 reflects significant financial challenges faced by Tianjin TEDA Biomedical Engineering Co. Ltd. Declining revenue, persistent losses, and high leverage present major risks. Technical indicators also suggest a lack of strong momentum. Valuation metrics are concerning due to ongoing losses and no dividend yield. Without positive developments in financial stability or market momentum, the outlook remains cautious.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. The company operates in two segments, Biological Compound Fertilizers Products, and Elderly Care and Health Care Services. Its biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formula that are used for the facilitation of balanced growth of grains, fruits, and vegetables. The company is also involved in the provision of integrated elderly and health care; and elderly equipment leasing services, as well as consulting, advisory, and assessment services. In addition, it provides and licenses electroencephalography photography (EEG) diagnosis detection services; and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation business; and provision of soil environmental quality standards research services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.

How the Company Makes Money

Tianjin TEDA Biomedical Engineering Co. Ltd. primarily generates revenue through the sale of its biotechnology products and services. The company's key revenue streams include the production and distribution of medical and health-related products, which are sold to healthcare providers and consumers. Additionally, the company may engage in partnerships or collaborations with other entities in the biomedical field, enhancing its market reach and product development capabilities. Revenue is also likely earned through licensing agreements and intellectual property related to its research and development efforts.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

Tianjin TEDA Biomedical Engineering Co. Ltd. is experiencing significant financial instability. The income statement highlights a declining revenue trend and consistent net losses. The balance sheet reveals a high Debt-to-Equity ratio, indicating heavy reliance on debt. Cash flow issues are evident with consistently negative operating cash flow, underscoring liquidity challenges.

Income Statement

The income statement reveals a declining trend in revenue, with Total Revenue decreasing from 476 million in 2021 to 385 million in 2024. Gross Profit Margin has narrowed significantly, and the company has been consistently incurring net losses, with a Net Income of -27.8 million in 2024. The EBIT and EBITDA margins are negative, indicating operational inefficiencies and challenges in maintaining profitability.

Balance Sheet

The balance sheet shows a weak financial structure with a high Debt-to-Equity ratio, increasing from 0.38 in 2019 to 7.22 in 2024, indicating heavy reliance on debt financing. Stockholders' Equity has diminished substantially, impacting the Equity Ratio, which fell to 6.66% in 2024. The company’s high leverage poses significant financial risk.

Cash Flow

Cash flow analysis points to severe issues, with Operating Cash Flow consistently negative, signaling poor cash generation ability. Free Cash Flow has been negative over multiple years, showing challenges in maintaining liquidity. The lack of positive cash flow ratios suggests difficulties in converting profits into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
423.65M	385.48M	398.00M	449.68M	476.38M	369.36M
	Gross Profit
26.63M	16.97M	21.37M	16.40M	45.60M	40.39M
	EBIT
-10.68M	-28.38M	-9.83M	-20.80M	-4.44M	-21.75M
	EBITDA
5.77M	-20.19M	4.79M	-2.26M	-29.86M	-14.65M
	Net Income Common Stockholders
-13.03M	-27.80M	-20.16M	-26.65M	-44.78M	-50.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
92.73M	25.40M	5.93M	9.55M	29.78M	35.53M
	Total Assets
310.05M	332.53M	303.28M	337.20M	347.60M	392.92M
	Total Debt
110.53M	159.92M	83.56M	96.01M	90.34M	54.65M
	Net Debt
92.33M	134.52M	77.62M	89.16M	63.90M	41.12M
	Total Liabilities
251.00M	304.09M	238.70M	253.48M	237.24M	237.77M
	Stockholders Equity
45.83M	22.15M	49.95M	72.67M	100.78M	143.04M
Cash Flow		Free Cash Flow
7.30M	0.00	-15.62M	-21.62M	-40.38M	21.96M
	Operating Cash Flow
8.04M	0.00	-13.15M	-12.82M	-6.68M	35.99M
	Investing Cash Flow
-748.74K	0.00	-467.44K	-12.93M	-8.51M	-26.51M
	Financing Cash Flow
4.97M	0.00	12.73M	6.17M	28.10M	-20.19M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.43, and above the 200-day MA of 0.34, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 31.66 is Neutral, neither overbought nor oversold. The STOCH value of 54.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$2.04B	-1.23	-21.09%	3.96%	2.90%	-30.45%
8189	39 Underperform	HK$832.42M	―	-81.86%	―	-4.88%	-34.75%
PIAIF		$127.66B	6.18		7.26%	―	―
SBMFF		$12.96B	51.81	6.14%	1.06%	―	―
CHJTF		$13.26B	19.73	13.20%	2.55%	―	―
SHWGF		$3.55B	12.17	8.95%	4.36%	―	―
CL4		€9.10B	22.14	28.95%	5.22%	―	―